Morgan Stanley initiated coverage of AstraZeneca with an Overweight rating and $85 price target. The analyst added six American depository receipts to the firm’s European Union Pharmaceuticals coverage. The stock’s fundamental views are fully aligned with those the firm has on the underlying stocks, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- AstraZeneca says Imfinzi combo improved survival in carcinoma patients
- AstraZeneca reports Voydeya granted regulatory approval in Japan
- AstraZeneca price target raised to 13,400 GBp from 12,900 GBp at Morgan Stanley
- AstraZeneca downgraded to Sell from Buy at UBS